Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: A mixed treatment comparison of randomized controlled trials
References (86)
- et al.
Efficacy of newer generation antipsychotics in the treatment of schizophrenia
Psychoneuroendocrinology
(2003) - et al.
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?
Lancet
(1998) - et al.
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia
Schizophr Res.
(2006) - et al.
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia
Psychoneuroendocrinology
(2006) - et al.
A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The Quetiapine Experience with Safety and Tolerability (QUEST) study
Clin Ther.
(2001) - et al.
Olanzapine vs risperidone in the management of schizophrenia: A randomized double-blind trial in Australia and New Zealand
Schizophr Res.
(2003) - et al.
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization
Schizophr Res.
(2006) - et al.
Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: Results from a randomized, open-label, 1-year trial
Value Health.
(2006) - et al.
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study
J Psychiatr Res.
(2006) - et al.
Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
Biol Psychiatry.
(1997)
Sexual dysfunction and antipsychotic treatment
Psychoneuroen-docrinology.
Obesity as a risk factor for an-tipsychotic noncompliance
Schizophr Res.
Olanzapine versus placebo and haloperidol: Acute phase results of the North American doubleblind olanzapine trial
Neuropsychopharmacology.
Clozaril (clozapine) 25 mg and 100 mg tablets [product characteristics]
Clozapine versus typical neuroleptic medication for schizophrenia
Cochrane Database Syst Rev.
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
Am J Psychiatry.
Effects of antipsychotic treatment on tardive dyskinesia: A 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study
J Clin Psychiatry.
Side effect profile of atypical antipsychotic medications and comparison to conventional antipsychotics
Soc Psihijatrija.
Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?
Ann Clin Psychiatry.
Atypical antipsychotics in the treatment of mania: A meta-analysis of randomized, placebo-controlled trials
J Clin Psychiatry.
New antipsychotics and schizophrenia: A review on efficacy and side effects
Curr Med Chem.
Comparison of the efficacy and acceptability of atypical antipsychotic drugs: A meta-analysis of randomized, placebo-controlled trials
J Med Assoc Thai.
Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care
Development of a review protocol
Bias in treatment assignment in controlled clinical trials
N Engl J Med.
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
JAMA.
WinBUGS—a Bayesian modelling framework: Concepts, structure, and extensibility
Stat Comput.
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence
BMJ.
Combination of direct and indirect evidence in mixed treatment comparisons
Stat Med.
The direct use of likelihood for significance testing
Stat Comput.
Indirect comparisons of treatments based on systematic reviews of randomised controlled trials
Int J Clin Pract.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
N Engl J Med.
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
J Clin Psychopharmacol.
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olan-zapine, risperidone, or haloperidol
Arch Gen Psychiatry.
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder [published correction appears in Am J Psychiatry. 2001;158:1759]
Am J Psychiatry.
Changes in cognitive functioning with risperidone and olanzapine treatment: A large-scale, double-blind, randomized study
Psychopharmacology (Berl).
Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning
J Clin Psychopharmacol.
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms
J Clin Psychopharmacol.
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder [published correction appears in Am J Psychiatry. 2002;159:2132]
Am J Psychiatry.
Antipsychotic-induced weight gain and therapeutic response: A differential association
J Clin Psychopharmacol
A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning
J Sex Marital Ther.
Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia
Neuropsychopharmacology
Cited by (40)
The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design
2021, Revista de Psiquiatria y Salud MentalCitation Excerpt :The complete methods and the inter-rater reliability results have been described previously in a specific work.76 The assessment of adherence has been performed with standardized scales and complemented with various biochemical measurements such as drug concentrations in blood or saliva; The Scale to Assess Unawareness of Mental Disorder (SUMD),77 which is a semi-structured open interview that evaluates global insight, insight into illness and insight into symptoms; the Morisky Green Levine Medication Adherence Scale (MGLS), used for measuring the extent of medication non-adherence,78 and the Tolerability and Quality of Life Questionnaire (TOOL), which evaluates the impact of the adverse effects of antipsychotic drugs on patients.79 Monitoring of antipsychotic concentrations is recommended for all these therapeutic agents that have limited therapeutic ranges and are at high risk for associated severe adverse effects.
Exhaustive in silico design and screening of novel antipsychotic compounds with improved pharmacodynamics and blood-brain barrier permeation properties
2023, Journal of Biomolecular Structure and DynamicsPharmacotherapy of neuropsychiatric disturbances
2021, Brain Injury Medicine, Third Edition: Principles and PracticePrevalence and pattern of antipsychotic induced movement disorders in a tertiary care teaching hospital in India–a cross-sectional study
2018, International Journal of Psychiatry in Clinical PracticeInflammation: Opportunities for treatment stratification among individuals diagnosed with mood disorders
2017, Dialogues in Clinical Neuroscience